Drugs/Recall·openFDA/drug

Shimoga Chemicals — Class II: Clomiphene Citrate USP Active Pharmaceutical Ingredient (CAS : 50-41-9), Net Weight a)1 KG

MediumPublished Jul 15, 2026· AI-analyzed Jul 22, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Shimoga Chemicals has initiated a Class II recall for several net weight configurations of Clomiphene Citrate USP Active Pharmaceutical Ingredient (API) due to documented cGMP deviations. The recall is currently classified as ongoing and involves products manufactured at their facility in Maharashtra, India.

Who it affects

This recall affects pharmaceutical manufacturers, compounding pharmacies, and distributors who utilize Shimoga Chemicals Clomiphene Citrate API (CAS: 50-41-9) in the production of finished dosage forms.

Why it matters

A Class II recall due to cGMP deviations at the API level suggests potential deficiencies in the manufacturing process, facility environment, or quality control systems. While the source does not specify the exact nature of the deviations, such failures typically call into question the identity, strength, quality, or purity of the raw materials, potentially necessitating downstream recalls of finished drug products.

Practical takeaway

Supply chain and procurement teams should immediately quarantine any Clomiphene Citrate API sourced from Shimoga Chemicals. Quality units should conduct a risk assessment for any finished drug products manufactured using these batches to determine the impact of the reported cGMP deviations on product quality.

FDA source material

Class II. Reason: cGMP deviations. Product: Clomiphene Citrate USP Active Pharmaceutical Ingredient (CAS : 50-41-9), Net Weight a)1 KG (NDC 84849-000-01), b) 500 g (NDC 84849-000-02), (c) 100 g (NDC 84849-000-03), Rx Only, Shimoga Chemicals Address -W-57A, MIDC Kupwad Samgli, Maharashtra, 416436, India.. Firm: Shimoga Chemicals (Sangli N/A India). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.